Arrowhead Pharmaceuticals, Inc.
Compositions and methods for inhibiting expression of RRM2 genes

Last updated:

Abstract:

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a RRM2 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a RRM2 gene using said pharmaceutical composition; and methods for inhibiting the expression of RRM2 in a cell.

Status:
Grant
Type:

Utility

Filling date:

27 Feb 2018

Issue date:

14 Apr 2020